BRIEF-Cspc Pharmaceutical Enters License Deal With Sinocelltech For Anti-CD20 Monoclonal Antibody

Oct 8 (Reuters) - CSPC Pharmaceutical Group Ltd:

* ENTERS DEAL WITH SINOCELLTECH TO LICENSE AND COMMERCIALIZE ANTI- CD20 MONOCLONAL ANTIBODY FOR INJECTION DEVELOPED BY SINOCELLTECH

* CO TO PAY SINOCELLTECH UPFRONT & DEVELOPMENT MILESTONE PAYMENTS OF UP TO RMB650 MILLION

* PURSUANT TO DEAL, CO WILL BE GRANTED EXCLUSIVE RIGHT FOR PRODUCT BY SINOCELLTECH TO APPLY FOR PRODUCT APPROVAL IN CHINA Source text for Eikon: Further company coverage:

Advertisement